Alnylam: A Loud Silence (A) Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• Cash and marketable securities: 1.1 billion dollars as of late 2016.
• Market capitalization loss: Approximately 3 billion dollars or 48 percent of company value within 24 hours of the Revusiran announcement.
• Research and development spend: Historically high as a percentage of revenue, typical for pre-commercial biotech.
• Funding status: Sufficient runway to reach 2017 readouts for Patisiran.

Operational Facts

• Technology base: RNA interference (RNAi) using small interfering RNA (siRNA) to silence disease-causing genes.
• Delivery platforms: Two distinct methods including Lipid Nanoparticles (LNP) and GalNAc-conjugate delivery.
• Revusiran status: Phase 3 ENDEAVOUR trial for hereditary ATTR amyloidosis with cardiomyopathy.
• Safety data: 18 deaths in the Revusiran treatment arm compared to 2 deaths in the placebo arm.
• Pipeline breadth: Multiple programs in clinical stages including Patisiran (LNP) and several next-generation GalNAc (ESC-GalNAc) candidates.

Stakeholder Positions

• John Maraganore (CEO): Focused on the long-term survival of the RNAi platform and maintaining investor confidence.
• Akshay Vaishnaw (Chief Medical Officer): Tasked with determining if the toxicity is molecule-specific or platform-wide.
• Investors: Panic-driven selling based on the fear that the entire GalNAc delivery platform is unsafe.
• FDA: Requires immediate and transparent reporting on the mortality imbalance.

Information Gaps

• Mechanistic cause of death: The specific biological reason why Revusiran patients experienced higher mortality remains unknown.
• Comparative safety: Lack of long-term human data for ESC-GalNAc (next-generation) compared to the first-generation GalNAc used in Revusiran.
• Dose-response relationship: Whether lower doses of Revusiran would have avoided the safety signal.

2. Strategic Analysis

Core Strategic Question

• Does the mortality imbalance in the Revusiran trial indicate a terminal flaw in the RNAi mechanism, or is it an isolated failure of a specific chemical delivery vehicle?

Structural Analysis

The company faces a crisis of confidence in its modularity thesis. The core assumption of Alnylam is that once a delivery method is proven safe, multiple drugs can be developed using that same method. The Revusiran failure threatens this entire pipeline logic.

Using a Pipeline Risk Assessment:

• Platform Risk: High. If GalNAc is toxic, 80 percent of the future pipeline is non-viable.
• Molecule Risk: Moderate. Revusiran used a first-generation version of GalNAc at very high doses.
• Execution Risk: Low. The company identifies the signal early and acts decisively.

Strategic Options

Option 1: Immediate Cessation and Pivot. Terminate the Revusiran program entirely. Shift all resources to Patisiran (LNP-based) and next-generation ESC-GalNAc programs. This isolates the failure to a specific generation of technology.

• Rationale: Protects the reputation of the newer, more potent technology.
• Trade-offs: Abandons years of investment and a lead product candidate.
• Requirements: Rapid data analysis to prove ESC-GalNAc is chemically distinct.

Option 2: Pause and Investigate. Halt all GalNAc trials until the cause of death is found. Maintain Patisiran development.

• Rationale: Maximum safety for patients.
• Trade-offs: Significant delays to market entry for the entire pipeline; likely leads to a further stock price collapse.
• Requirements: Extensive laboratory work to find a mechanism of toxicity.

Preliminary Recommendation

Alnylam must pursue Option 1. The company cannot afford the time required for a full mechanistic investigation while the entire platform is under suspicion. By terminating Revusiran and highlighting the differences in potency and dosing between the old and new GalNAc generations, Alnylam can ringfence the damage.

3. Implementation Planning

Critical Path

• Immediate Action: Unblind the ENDEAVOUR trial data to perform a detailed safety analysis.
• External Communication: Conduct an emergency investor call to explain the technological difference between Revusiran (V1) and the rest of the pipeline (V2/ESC).
• Regulatory Engagement: Submit all findings to the FDA within 30 days to ensure other trials are allowed to continue.
• Resource Reallocation: Move the Revusiran clinical operations team to support the Patisiran APOLLO trial, ensuring no delays in the LNP-based readout.

Key Constraints

• Data Availability: The speed at which the company can analyze the mortality data will dictate the duration of market uncertainty.
• Scientific Credibility: The company must provide a plausible explanation for why V2 GalNAc will not replicate the V1 toxicity.
• Capital Access: While the company has 1.1 billion dollars, a sustained low stock price prevents future equity raises if the Patisiran trial fails.

Risk-Adjusted Implementation Strategy

The strategy assumes the toxicity is dose-related. Because ESC-GalNAc is ten times more potent, it uses significantly lower doses. The implementation focuses on this dose-differential as the primary defense. If the FDA places a clinical hold on all GalNAc programs, the company must immediately pivot to an LNP-only focus to survive, which would reduce the long-term valuation by 70 percent.

4. Executive Review and BLUF

BLUF

Terminate Revusiran immediately. The 18 to 2 mortality imbalance in the ENDEAVOUR trial is a catastrophic safety signal that cannot be mitigated through dose adjustment or patient screening. The company must pivot to its next-generation ESC-GalNAc platform and its LNP-based Patisiran program. Survival depends on convincing the market that Revusiran is a first-generation outlier characterized by high-dose chemical toxicity, not a fundamental failure of RNA interference. Maintain the 2017 timeline for Patisiran data as the primary catalyst for valuation recovery. Binary Verdict: APPROVED FOR LEADERSHIP REVIEW.

Dangerous Assumption

The analysis assumes that the mortality in the Revusiran trial is caused by the high dose of the first-generation GalNAc conjugate rather than the silencing of the TTR gene itself. If the toxicity is a result of the RNAi mechanism in the heart, the entire ATTR program, including Patisiran, is at risk.

Unaddressed Risks

Unconsidered Alternative

The team did not consider a strategic sale or partnership for the LNP platform. If the GalNAc platform is compromised, the LNP technology becomes the only viable asset. Selling or licensing this asset now, while Patisiran is in Phase 3, could secure the cash necessary to rebuild the company if the GalNAc platform is permanently halted by regulators.